Newsletters arkiv förslag

Alternativ 1

Alternativ 2

Alternative 2

Newsletter #2 – 2022

The Swedish pharma and life sciences litigation newsletter IN THIS ISSUE PHARMA – Update on Novartis v Zentiva, Glenmark, Teva, and Mylan over fingolimod products PHARMA – Teva v Bristol-Myers Squibb over the validity of apixaban…

Read More

Newsletter #1 – 2022

The Swedish pharma and life sciences litigation newsletter IN THIS ISSUE Pharma: Novartis v Zentiva over generic fingolimod product Medtech: Edwards Lifesciences v Meril Life Sciences over transcatheter heart valves Life sciences: Illumina v MGI over…

Read More
1 2

Alternativ 4

Scroll to Top